Efficacy and safety of nanoparticle albumin ‐bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non‐small cell lung cancer: A multicenter Phase 2 clinical trial

ConclusionsNab-paclitaxel therapy improved ORR after PD-(L)1 inhibitor treatment failure with a durable response of 13% and acceptable toxicities in patients with advanced NSCLC.

Source: Cancer Medicine - April 21, 2023 Category: Cancer & Oncology Authors: Tomoaki Sonoda, Yukihiro Umeda, Yoshiki Demura, Toshihiko Tada, Koki Nakashima, Masaki Anzai, Makiko Yamaguchi, Akikazu Shimada, Masahiro Ohi, Chisato Honjo, Yuko Waseda, Masaya Akai, Tamotsu Ishizuka Tags: RESEARCH ARTICLE Source Type: research